Welcome to our dedicated page for Iteos Therapeutics SEC filings (Ticker: ITOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot a pivotal clinical update buried in Iteos Therapeutics’ 200-page 10-K? Biotech filings are packed with trial protocols, licensing clauses and detailed risk factors that can slow any portfolio review. Investors tracking immuno-oncology names need to know when cash runway shortens, how TIGIT antibody studies progress, and whether management sells shares ahead of data readouts.
Our platform solves this in two clicks. Stock Titan’s AI parses every new document the moment it hits EDGAR, turning dense text into clear takeaways. Need the Iteos Therapeutics quarterly earnings report 10-Q filing? We highlight R&D spend, collaboration revenue and changes in cash balance. Looking for Iteos Therapeutics insider trading Form 4 transactions? Real-time alerts surface executive stock moves and option exercises. Wondering what a sudden 8-K means for the pipeline? Our summaries explain material events, partnerships or trial holds without biotech jargon.
Here’s what you can explore today:
- 10-K & 10-Q: Cash runway, trial cost projections and key risk disclosures—Iteos Therapeutics annual report 10-K simplified
- Form 4: Iteos Therapeutics Form 4 insider transactions real-time for timely insight into executive sentiment
- Proxy (DEF 14A): Drill into Iteos Therapeutics proxy statement executive compensation to see equity grants tied to milestone achievements
- 8-K: Iteos Therapeutics 8-K material events explained—from FDA feedback to collaboration amendments
Whether you’re comparing quarter-over-quarter burn, monitoring dilution risk in shelf registrations, or simply understanding Iteos Therapeutics SEC documents with AI, Stock Titan delivers the clarity professionals expect, updated in real time.
iTeos Therapeutics (ITOS) entered into a definitive Agreement & Plan of Merger on 18-Jul-2025 with Concentra Biosciences.
- Tender offer: $10.047 cash per share plus one contingent value right (CVR); offer must start within 10 business days.
- Key conditions: more than 50% of voting shares tendered, no legal restraints, customary reps & warranties, and minimum $475 m Closing Net Cash; no financing condition.
- Post-offer merger: Merger Sub will be merged into ITOS under DGCL §251(h), creating a wholly-owned Concentra subsidiary without further shareholder vote.
- CVR economics: 100% of cash above $475 m and 80% of proceeds from divestiture of specified pipeline assets completed within six months of closing, payable up to eight years.
- Protections: Tang Capital issued a limited guaranty capped at $465 m; board unanimously recommends the transaction; directors & officers (≈0.6% ownership) signed tender support agreements.
- Break fees: $8.4 m if ITOS accepts a superior proposal; Concentra can recover up to $0.5 m expenses if net cash threshold missed.
- Related items: ITOS terminated its 2020 ESPP and reached a Mutual Termination Agreement with GSK requiring a $32 m payment.
- Timeline: Offer/merger must close by 16-Oct-2025 or either party may terminate.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
What is the primary focus of Iteos Therapeutics?
Which therapeutic areas does the company specialize in?
How are Iteos Therapeutics' products designed?
What distinguishes Iteos Therapeutics in the competitive biopharmaceutical landscape?
Can you explain the significance of their adenosine A2A receptor antagonist?
What role does tumor immunology play in Iteos' approach?
How does the company communicate its clinical progress to stakeholders?
What are the primary components of Iteos Therapeutics' pipeline?
